Dengue Vaccine R&D Collaboration

Partnership Objectives

  1. Conduct research and development from preclinical through late stage development of an efficacious dengue vaccine candidate.
  2. Conduct the clinical development and regulatory filing of the vaccine candidate in Brazil considering the epidemiological situation and the medical need in the country.
  3. Exchange scientific ideas and technologies between the partners and more specifically to enhance vaccine development capabilities at Fiocruz in Brazil.

The alliance fosters the cross-fertilisation of ideas and technology, as scientists from GSK and Fiocruz work across facilities in Brazil and Belgium. The alliance fosters the cross-fertilisation of ideas and technology, as scientists from GSK and Fiocruz work across facilities in Brazil and Belgium. Copyright GSK

What are the health needs and challenges?

The prevention of dengue fever, a mosquito-borne disease, is a priority in endemic countries in which 2.5 billion people are globally at risk of infection by dengue virus. 

Description of partnership activities and how they address needs and challenges

GSK Biologicals and the Oswaldo Cruz Foundation (FioCruz) initiated their first collaboration with an agreement to supply oral polio vaccines in 1985.  Since then, GSK Biologicals and Fiocruz have formed several strategic alliances to provide Brazilians with key vaccines, including vaccines against Haemophilus influenzae type b (Hib), MMR (measles, mumps and rubella) and rotavirus. This is the partners’ first collaboration on an R&D center that will focus on the development of new vaccines.

The extended vaccine partnership between GSK and FioCruz aims to create a joint R&D initiative to develop a vaccine for dengue fever. Scientists from GlaxoSmithKline in Belgium, where GSK’s vaccines division is headquartered, and FioCruz in Brazil, will be involved in the new partnership which should help to enhance Brazilian vaccine R&D capacity. Scientists from GSK and Fiocruz are working together in both Brazil and Belgium to develop a candidate vaccine against dengue fever.

The partnership establishes a research and development program that will be conducted jointly by GSK and Fiocruz to develop a vaccine for the prevention of dengue fever; the sharing of specific knowledge and development expertise between the partners is thought to be key to accelerate the development of the vaccine candidate towards its registration in Brazil at first. 

The challenges of the dengue vaccine approach (use of four serotypes and potential interferences, role of the neutralizing antibodies to avoid promoting more severe form of the disease) are addressed by the common development program which is reviewed and updated regularly by the joint management committee which is governing the collaboration between the GSK and Fiocruz partners. 

Attached to the Brazilian Ministry of Health, Fiocruz is the most prominent science and technology health institution in Latin America given the mission of fighting the great problems of public health in Brazil. Alongside research development the institution works in production of vaccines, drugs, diagnostic kits, education and training of human resources, quality control of products and services and the implementation of social programs.

Lessons learned                            

The alliance fosters the cross-fertilisation of ideas and technology, as scientists from GSK and Fiocruz work across facilities in Brazil and Belgium. GSK has a long history of working with partners on every step of its vaccine pipeline, from development to manufacturing and distribution.

Summary of impact and forward looking information

Therefore, GSK and Fioruz are evaluating an adjuvant inactivated dengue virus vaccine that is anticipated to have a superior profile compared to live vaccines.

Partnership information

Company(ies) GlaxoSmithKline

Partner(s) Fundação Oswaldo Cruz (Fiocruz)

Type of Partner(s) NGOs

Therapeutic Focus Neglected Tropical Diseases

Disease(s) Dengue

Program Type(s) Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Prevention Programs - Vaccines, Research & Development - Development of Treatments

Targeted Population(s) Children, Elderly, General population, Men, Mothers, People with low income, Women, Youth

Region(s) Latin America & Caribbean

Number of Countries 1

Country(ies) Brazil

Start Date 2010

More information Press Release

Anticipated completion date 2020

« The partnership will enhance Brazilian R&D capacity, improve the health of our citizens and cement Brazil’s role as a leading partner on vaccines. »

Dr. Paulo Gadelha, President of Fiocruz